Cost effectiveness (CE) of blinatumomab (BLIN) vs inotuzumab ozogamicin (INO) in adult patients with relapsed or refractory (R/R) acute lymphoblastic leukemia (ALL) with no more than one prior salvage therapy (S0/S1) from a US payer perspective.

Abstract

e18895Background: To estimate Incremental CE Ratio (ICER = ∆Cost / ∆QALY [Quality Adjusted Life Year]) of BLIN vs INO in adults with R/R S0/S1 ALL based on matching-adjusted indirect treatment comp...